By Mill Chart
Last update: Oct 13, 2023
Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as a growth stock which is not overvalued. NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:EXEL was assigned a score of 7 for growth:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:EXEL, the assigned 6 reflects its valuation:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NASDAQ:EXEL, the assigned 7 for health provides valuable insights:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:EXEL has earned a 7 out of 10:
More Affordable Growth stocks can be found in our Affordable Growth screener.
Our latest full fundamental report of EXEL contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
EXELIXIS INC
NASDAQ:EXEL (4/26/2024, 7:00:02 PM)
After market: 23.7 0 (0%)23.7
+0.17 (+0.72%)
Learn about the top three biotech stocks to take advantage of these companies' promising futures and pharmaceutical advances.
EXELIXIS INC (NASDAQ:EXEL) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
These stocks are worth buying in most months of the year.
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
You don't need to be a millionaire to get started. Investing on a budget can work, too.